Machine signal
Active cluster sell — 3 distinct insiders, $14.4M, window ends Sep 14, 2026.
Figures computed from official regulatory filings — .
Analysttarget 145.79 USD (+76%) · consensus 4.71/5 · 14 buy · 0 hold · 0 sell
Ownershipinsiders 1.3% · institutions 111.77% · short 12.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Mirum Pharmaceuticals, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
62 buys142 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| BJERKHOLT ERICtrack record | Sell | $978.1K | Unusual size | SEC |
| BJERKHOLT ERICtrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BJERKHOLT ERICtrack record | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Peetz Christophertrack record | Sell | $2.1M | SEC |
| Peetz Christophertrack record | Sell | $815.2K | SEC |
| Peetz Christophertrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Peetz Christophertrack record | Exercise | $88.1K | SEC |
| Howe Jolanda | Sell | $65.8K | SEC |
| Howe Jolanda | Exercise | $250.8K | Unusual size | SEC |
| Howe Jolanda | Sell | $4M | Unusual size | SEC |
| Howe Jolanda | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BJERKHOLT ERICtrack record | Sell | $599.5K | Unusual size | SEC |
| Peetz Christophertrack record | Sell | $1.2M | SEC |
| Peetz Christophertrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Peetz Christophertrack record | Sell | $230.3K | SEC |
| Peetz Christophertrack record | Sell | $597.2K | SEC |
| Peetz Christophertrack record | Exercise | $58.7K | SEC |
| Howe Jolanda | Sell | $193.7K | SEC |
| BJERKHOLT ERICtrack record | Sell | $37.5K | SEC |
| BJERKHOLT ERICtrack record | Sell | $65.4K | SEC |
| Peetz Christophertrack record | Sell | $213.4K | SEC |
| Peetz Christophertrack record | Exercise | $58.7K | SEC |
| Peetz Christophertrack record | Sell | $244.4K | SEC |
| Peetz Christophertrack record | Sell | $511.5K | SEC |
| Peetz Christophertrack record | Sell | $1.5M | SEC |